Lexaria Bioscience Earnings Estimates, EPS & Revenue | NASDAQ:LEXX

Comments

Lexaria Bioscience Corp Earnings Estimates

LEXXNASDAQ

Trade with Public

$0.9100

0.00510.56%

At close: Apr 10, 5:00 PM EST

$0.9800

0.077.69%

After Hours: Apr 10, 7:39 PM EST

Overview NewsEarningsAnalyst Ratings Insider Trades Short Interest Stock Report

Lexaria Bioscience Earnings Estimates, EPS & Revenue | NASDAQ:LEXX

Lexaria Bioscience (LEXX) is scheduled to report Q2 earnings on April 24, 2026. Analysts estimate EPS of $-0.08 and quarterly revenue of $70.00K.

In the most recent quarter (Q1), Lexaria Bioscience reported EPS of $-0.07, beating estimates of $-0.08 by 0.13%. Revenue came in at $0.00, missing the estimate of $70.00K by 1.00%.

Lexaria Bioscience has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Lexaria Bioscience has averaged an EPS surprise of 0.19% and a revenue surprise of 0.87%.

Earnings Date

Apr 24

EPS Estimate

$-0.080

Quarterly Revenue Estimate

$70.00K

Annual Revenue
(as of Nov 30)

$522.00K

Lexaria Bioscience Earnings History

Analyze the earnings history of Lexaria Bioscience using advanced sorting and filters.

Loading calendar...

Lexaria Bioscience (LEXX) Earnings Per Share

The chart below shows Lexaria Bioscience's reported EPS compared to analyst estimates over recent quarters.

Lexaria Bioscience (LEXX) Revenue

The chart below shows Lexaria Bioscience's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Lexaria Bioscience (NASDAQ:LEXX) reporting earnings?

Lexaria Bioscience (LEXX) is scheduled to report earnings on April 24, 2026. The last reported earnings were for reported on January 13, 2026 for Q1.

What were the latest earnings per share (EPS) for Lexaria Bioscience (NASDAQ:LEXX)?

The Actual EPS was $-0.07, which beat the estimate of $-0.08.

What were Lexaria Bioscience’s (NASDAQ:LEXX) revenues?

The Actual Revenue was $0.00, which missed the estimate of $70.00K.

People Also Watch

Incannex Healthcare Inc

NASDAQ:IXHL

$3.12

VYNE Therapeutics Inc

Cadrenal Therapeutics Inc

NASDAQ:CVKD

$4.67

-1.89%

Tvardi Therapeutics Inc

Lexaria Bioscience Earnings Estimates, EPS & Revenue | NASDAQ:LEXX

Lexaria Bioscience (LEXX) is scheduled to report Q2 earnings on April 24, 2026. Analysts estimate EPS of $-0.08 and quarterly revenue of $70.00K.

In the most recent quarter (Q1), Lexaria Bioscience reported EPS of $-0.07, beating estimates of $-0.08 by 0.13%. Revenue came in at $0.00, missing the estimate of $70.00K by 1.00%.

Lexaria Bioscience has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Lexaria Bioscience has averaged an EPS surprise of 0.19% and a revenue surprise of 0.87%.

Earnings Date

Apr 24

EPS Estimate

$-0.080

Quarterly Revenue Estimate

$70.00K

Annual Revenue
(as of Nov 30)

$522.00K